Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 36238278)

  • 1. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
    Shan J; Han D; Shen C; Lei Q; Zhang Y
    Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
    Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
    World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
    Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
    Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
    Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
    Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].
    Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
    Liao L; Xu H; Zhao Y; Zheng X
    Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
    Naimi A; Mohammed RN; Raji A; Chupradit S; Yumashev AV; Suksatan W; Shalaby MN; Thangavelu L; Kamrava S; Shomali N; Sohrabi AD; Adili A; Noroozi-Aghideh A; Razeghian E
    Cell Commun Signal; 2022 Apr; 20(1):44. PubMed ID: 35392976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
    Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
    Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic strategies for gastric cancer targeting immune cells: Future directions.
    Zhao Y; Bai Y; Shen M; Li Y
    Front Immunol; 2022; 13():992762. PubMed ID: 36225938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.